We have updated the ordering process to allow all products and services to be purchased with a single PO, please address all POs to Horizon Discovery Biosciences Limited. Contact us for assistance.

On the Horizon

Leading news, knowledge, and industry trends in genetic research

Screening

19 result(s)









The clinical success rate of new oncology drugs is only 3.4% compared to 20.9% in other disease types (Wong et al, 2018). One contributing factor to this issue is the testing systems used, with two-dimensional (2D) monolayer assay formats as the traditional mainstay of high throughput screening. Although 2D monolayer assays have identified many successful drugs, it is increasingly recognised that they do not accurately model key aspects of the three-dimensional (3D) tumour environment. Therefore, the adoption of high throughput screening approaches using 3D assays to complement 2D approaches could substantially improve prediction of clinical outcomes and reduce the high failure rate of cancer drugs in clinical trials.